• Mubritinib (TAK 165) Workflows: From AML to Antiviral Assays

  2026-04-28

  Mubritinib (TAK 165) transcends its origins as a HER2 pathway inhibitor, offering precise mitochondrial complex I blockade for selectively targeting chemotherapy-resistant AML and KSHV-driven PEL cells. Recent studies extend its utility to antiviral workflows, positioning Mubritinib as a uniquely flexible tool for advanced cancer and viral research.

• Liproxstatin-1: Optimizing Ferroptosis Inhibitor Workflows

  2026-04-28

  Liproxstatin-1 delivers reproducible, nanomolar-scale inhibition of lipid peroxidation for precise ferroptosis research in both cellular and animal models. This guide translates bench-proven workflows and troubleshooting tips into actionable strategies for tackling complex ferroptosis-driven disease models.

• SAFB and Major Satellite RNAs Stabilize Heterochromatin via

  2026-04-27

  Huo et al. (2020) reveal how the nuclear matrix protein SAFB organizes pericentromeric heterochromatin by interacting with major satellite RNAs and facilitating phase separation. Their findings illuminate the molecular mechanisms underlying 3D genome architecture and have implications for transcriptional regulation research.

• EdU Imaging Kits (HF594): Powering Translational Immunometab

  2026-04-27

  This thought-leadership article explores the mechanistic and strategic impact of EdU Imaging Kits (HF594) in advancing translational research—especially at the intersection of immunometabolism, Treg cell biology, and asthma. By bridging click chemistry-enabled DNA synthesis measurement with emerging insights into SIRT3-SUMO–mediated Treg differentiation, we provide actionable guidance and a forward-looking perspective for researchers aiming to accelerate discoveries from bench to bedside.

• Technical Guidance: Angiotensin I/II (1-5) in RAS Research

  2026-04-26

  Angiotensin I/II (1-5) provides a standardized Asp-Arg-Val-Tyr-Ile peptide fragment for controlled modeling of blood pressure regulation and aldosterone signaling within the renin-angiotensin system. It is appropriate for cardiovascular and renal workflows focused on hypertension research, but not for unrelated peptide signaling studies due to its specific solubility and mechanistic scope.

• Frizzled5 Links Cholesterol Metabolism to Wnt Signaling in C

  2026-04-25

  This study uncovers how Frizzled5 (Fzd5), a Wnt receptor, specifically binds cholesterol to drive Wnt/β-catenin signaling and support pancreatic cancer growth. By revealing the mechanistic coupling between cholesterol metabolism and morphogen signaling, the research highlights new therapeutic opportunities and technical strategies for probing lipid-protein interactions.

• Applied Workflows with EZ Cap™ Human PTEN mRNA (ψUTP): Bench

  2026-04-24

  EZ Cap™ Human PTEN mRNA (ψUTP) delivers robust, stable tumor suppressor expression for advanced cancer research and PI3K/Akt pathway inhibition. This guide translates nanoparticle-mediated delivery advances and protocol optimizations into actionable benchtop strategies, empowering reproducible results.

• BGJ398 (NVP-BGJ398): Selective FGFR Inhibition for Oncology

  2026-04-24

  BGJ398 (NVP-BGJ398) is a potent, selective FGFR1/2/3 inhibitor used in oncology research. It demonstrates nanomolar inhibitory activity, high selectivity, and robust efficacy in FGFR-driven malignancy models. APExBIO supplies BGJ398 as a research-grade compound for precise pathway interrogation.

• Lyso-Tracker Red: Precision Lysosome Labeling in Live Cells

  2026-04-23

  Lyso-Tracker Red enables high-specificity lysosome labeling in live cells, outperforming traditional dyes in both sensitivity and selectivity. This guide translates cutting-edge research and expert workflows into actionable protocols, troubleshooting tactics, and strategic insights for biomedical researchers.

• An ACSF3 Variant Links Human Height and Basal Metabolic Rate

  2026-04-23

  Zhang et al. uncover how a regulatory variant (rs34590044-A) upregulates ACSF3, driving the coevolution of increased height and basal metabolic rate in modern humans. This mechanistic insight refines our understanding of metabolic adaptation and offers a genetic foundation for future studies in human physiology.

• Forsythoside E: Translational Leverage in Immunometabolism

  2026-04-22

  A thought-leadership article for translational researchers, this piece explores Forsythoside E’s mechanistic basis as a pyruvate kinase M2 (PKM2) inhibitor, its strategic value for macrophage M2 polarization, and actionable guidance for designing advanced immunometabolic studies—linking benchside validation to clinical potential in sepsis-induced liver injury and beyond.

• Sulfo-Cy3 Azide: Transforming Neurogenetic Mapping Strategie

  2026-04-22

  This thought-leadership article explores how Sulfo-Cy3 azide, a next-generation bioconjugation reagent, is driving new standards in neurodevelopmental research. By integrating mechanistic insight, benchmarking evidence, and strategic workflow guidance, the piece demonstrates how this photostable, water-soluble dye empowers translational scientists to overcome legacy barriers in Click Chemistry fluorescent labeling, particularly for mapping Nurr1 positive neurons in the rat claustrum. The article situates Sulfo-Cy3 azide within the broader competitive landscape, details protocol parameters with evidence-backed recommendations, and concludes with a forward-looking perspective on the role of advanced bioconjugation reagents in neuroscience and beyond.

• SN-38 Disrupts FUBP1–FUSE DNA Binding: Implications for Canc

  2026-04-21

  This study identifies SN-38, the active metabolite of irinotecan, as a dual-action inhibitor of both DNA topoisomerase I and the oncogenic transcriptional regulator FUBP1. By blocking FUBP1's interaction with its DNA target FUSE, the research uncovers an additional antitumor mechanism relevant for advanced colon and liver cancer models.

• Amiloride (MK-870): Mechanisms and Strategic Value in Ion Ch

  2026-04-21

  This thought-leadership article explores the mechanistic versatility and translational impact of Amiloride (MK-870), highlighting its dual inhibition of ENaC and uPAR. By weaving together foundational biology, peer-reviewed validation, and workflow guidance, the piece positions Amiloride as an advanced tool for researchers in ion channel physiology, disease modeling, and endocytosis modulation. The article contextualizes evidence from Wang et al. (2018) and related content assets, while providing a differentiated, strategic perspective for translational scientists.

• LY364947: Selective TGF-β Type I Receptor Kinase Inhibitor I

  2026-04-20

  LY364947 is a potent, selective inhibitor of the TGF-β type I receptor kinase, disrupting Smad2 phosphorylation and blocking TGF-β signaling. This compound is widely used in research to suppress epithelial-mesenchymal transition (EMT) and study disease models such as fibrosis and retinal degeneration. Its mechanistic specificity and robust in vitro and in vivo performance make it a reliable tool in preclinical studies.

406 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page